ARTICLE | Company News
Covidien neurology, autoimmune news
July 15, 2013 7:00 AM UTC
Covidien completed the spin-off of its pharmaceuticals business - its Mallinckrodt plc subsidiary - into a separate public company. Mallinckrodt began trading on the NYSE under the ticker "MNK" on July 1. Covidien shareholders received one Mallinckrodt share for every eight Covidien shares held as of June 19 (see BioCentury, Dec. 19, 2011). ...